You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究下調平安好醫生(01833.HK)目標價至139元 評級「買入」
阿思達克 09-30 15:24
匯豐研究發表報告指,平安好醫生(01833.HK)宣布折讓8.5%配售8,000萬股,集資最多81.1億元,集資所得將用於進一步發展核心業務、擴充自建醫療團隊、增加科技研發投入及潛在戰略投資等。該行認為,是次配售總體益處大於股權被稀釋的影響,對其維持「買入」評級。

報告指出,配售後現有股東的持股被稀釋約7%,但所得資金可用於鞏固行業領先地位,而且公司目前仍在虧損狀態,股份被稀釋意義不大,預測配售後每股估值僅較前收市價折讓約1%。

該行指,配售短期內或削弱股價表現,將目標價由145元下調至139元,但相信長遠影響較正面,料其股價將受到線上醫療服務用戶上客加快所帶動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account